nor-Binaltorphimine (Synonyms: Norbinaltorphimine; NorBNI)

Name: nor-Binaltorphimine
Brand: MedChemExpress
SKU: HY-117040
Rating: 5.0 (7 reviews)

Cat. No.: HY-117040 Purity: 98.70%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

nor-Binaltorphimine (Norbinaltorphimine; NorBNI) is a selective, long-acting competitive antagonist of the κ-opioid receptor. nor-Binaltorphimine blocks κ-opioid receptor-mediated analgesic effects, and inhibits butorphanol-induced changes in κ-opioid receptor binding kinetics, desensitization and down-regulation. nor-Binaltorphimine suppresses specific opioid withdrawal symptoms, precipitates withdrawal behaviors in butorphanol-dependent rats, and serves as a molecular probe for studying κ-opioid receptor-agonist interactions. nor-Binaltorphimine is applicable to research related to neurological disorders such as pain.

For research use only. We do not sell to patients.

nor-Binaltorphimine Chemical Structure

CAS No. : 105618-26-6

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	Get quote
100 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 7 publication(s) in Google Scholar

Other Forms of nor-Binaltorphimine:

Norbinaltorphimine dihydrochloride In-stock

7 Publications Citing Use of MCE nor-Binaltorphimine

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Opioid Receptor Isoform Specific Products:

View All Isoforms

μ Opioid Receptor/MOR κ Opioid Receptor/KOR δ Opioid Receptor/DOR NOP Receptor/ORL1

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target^[1]

κ Opioid Receptor/KOR

Cellular Effect

Cell Line	Type	Value	Description	References
CHO	EC₅₀	0.039 K_e/nM Compound: nor BNI	Stimulation of U-69,593 binding at human recombinant Opioid receptor kappa 1 transfected into CHO cells. Stimulation of U-69,593 binding at human recombinant Opioid receptor kappa 1 transfected into CHO cells.	[PMID: 12672258]
CHO	EC₅₀	120 nM Compound: 1, norBNI	Agonist activity at human recombinant mu opioid receptor expressed in CHO cells by [35S]GTPgammaS binding assay Agonist activity at human recombinant mu opioid receptor expressed in CHO cells by [35S]GTPgammaS binding assay	[PMID: 20568781]
CHO	EC₅₀	18.9 K_e/nM Compound: nor BNI	Stimulation of DAMGO binding in recombinant human Opioid receptor mu 1 transfected into CHO cells Stimulation of DAMGO binding in recombinant human Opioid receptor mu 1 transfected into CHO cells	[PMID: 12672258]
CHO	EC₅₀	380 nM Compound: 1, norBNI	Agonist activity at human recombinant delta opioid receptor expressed in CHO cells by [35S]GTPgammaS binding assay Agonist activity at human recombinant delta opioid receptor expressed in CHO cells by [35S]GTPgammaS binding assay	[PMID: 20568781]
CHO	EC₅₀	4.42 K_e/nM Compound: nor BNI	Stimulation of [35S]GTP-gamma-S, binding at human recombinant Opioid receptor delta 1 transfected into CHO cells. Stimulation of [35S]GTP-gamma-S, binding at human recombinant Opioid receptor delta 1 transfected into CHO cells.	[PMID: 12672258]
CHO	EC₅₀	6 nM Compound: 1, norBNI	Agonist activity at human recombinant kappa opioid receptor expressed in CHO cells by [35S]GTPgammaS binding assay Agonist activity at human recombinant kappa opioid receptor expressed in CHO cells by [35S]GTPgammaS binding assay	[PMID: 20568781]
CHO	IC₅₀	0.28 nM Compound: norBNI	Antagonist activity against HA-tagged human recombinant kappa opioid receptor expressed in CHO cell membranes incubated for 1 hr by [35S]GTPgammaS binding assay Antagonist activity against HA-tagged human recombinant kappa opioid receptor expressed in CHO cell membranes incubated for 1 hr by [35S]GTPgammaS binding assay	[PMID: 25593096]
CHO	IC₅₀	2.9 nM Compound: norBNI	Antagonist activity at mouse kappa opioid receptor-1 expressed in CHO cell membranes assessed as inhibition of U50,488H-induced [35S]GTPgammaS binding incubated for 60 mins by scintillation spectroscopic analysis Antagonist activity at mouse kappa opioid receptor-1 expressed in CHO cell membranes assessed as inhibition of U50,488H-induced [35S]GTPgammaS binding incubated for 60 mins by scintillation spectroscopic analysis	[PMID: 27556704]
CHO	IC₅₀	4.6 nM Compound: norBNI	Antagonist activity against HA-tagged human recombinant kappa opioid receptor expressed in CHO cells assessed as inhibition of U69,593-induced ERK phosphorylation pre-incubated with compound before U69,593 stimulation for 10 mins Antagonist activity against HA-tagged human recombinant kappa opioid receptor expressed in CHO cells assessed as inhibition of U69,593-induced ERK phosphorylation pre-incubated with compound before U69,593 stimulation for 10 mins	[PMID: 25593096]
HEK293	EC₅₀	158 nM Compound: NorBNI	Increase of JNK phosphorylation in U50488 treated HEK293 cells expressing GFP tagged kappa opioid receptor Increase of JNK phosphorylation in U50488 treated HEK293 cells expressing GFP tagged kappa opioid receptor	[PMID: 17702750]
HEK293	IC₅₀	2.1 nM Compound: nor-BNI 1	Antagonist activity at human kappa opioid receptor expressed in HEK cells assessed as inhibition of dynorphin A-induced [35S]GTPgammaS binding Antagonist activity at human kappa opioid receptor expressed in HEK cells assessed as inhibition of dynorphin A-induced [35S]GTPgammaS binding	[PMID: 20719509]
HEK293	IC₅₀	212 nM Compound: nor-BNI 1	Antagonist activity at human mu opioid receptor expressed in HEK cells assessed as inhibition of DAMGO-induced [35S]GTPgammaS binding Antagonist activity at human mu opioid receptor expressed in HEK cells assessed as inhibition of DAMGO-induced [35S]GTPgammaS binding	[PMID: 20719509]
HEK293	IC₅₀	24 nM Compound: nor-BNI 1	Antagonist activity at human delta opioid receptor expressed in HEK cells assessed as inhibition of SNC-80-induced [35S]GTPgammaS binding Antagonist activity at human delta opioid receptor expressed in HEK cells assessed as inhibition of SNC-80-induced [35S]GTPgammaS binding	[PMID: 20719509]
U2OS	IC₅₀	2.5 nM Compound: norBNI	Antagonist activity against human kappa opioid receptor expressed in human U2OS cells co-expressing beta-arrestin2 pre-treated for 15 mins before U69,593 stimulation for 90 mins by DiscoveRx beta-arrestin2 recruitment based PathHunter assay Antagonist activity against human kappa opioid receptor expressed in human U2OS cells co-expressing beta-arrestin2 pre-treated for 15 mins before U69,593 stimulation for 90 mins by DiscoveRx beta-arrestin2 recruitment based PathHunter assay	[PMID: 25593096]

In Vitro

Nor-binaltorphimine (0.01 nM-0.1 μM; 120 min) displaces the binding of [³H]U-69,593 to κ-opioid receptors in rat cortical cell membranes. Its K_i value is 4.8 nM in saline-infused rats, while its potency increases 12-fold (K_i = 0.4 nM) in butorphanol-infused rats, indicating that κ-opioid receptors are hypersensitive to this antagonist^[2].
nor-Binaltorphimine (20-200 nM; 30 min) potently antagonizes κ-selective agonists in the longitudinal muscle of guinea pig ileum, while it exhibits extremely weak antagonistic effects on the μ-selective agonist morphine, with a κ/μ selectivity ratio of 19.2^[3].
nor-Binaltorphimine (20 nM; 30 min) potently antagonizes κ-selective agonists in rabbit vas deferens preparations^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Nor-binaltorphimine (30 μg; intracerebroventricular injection; single administration / twice daily; consecutive 10 days) acts as a selective, long-acting κ-opioid receptor antagonist in rats^[1].
Nor-binaltorphimine (12-100 nM/5 μl; intracerebroventricular injection; administered twice, at 3 hours before and 48 hours after the initiation of butorphanol infusion) blocks most naloxone-precipitated withdrawal symptoms in butorphanol-dependent rats, exerts a significant blocking effect on diarrhea, alleviates forepaw tremor, and prevents butorphanol-induced desensitization of κ-opioid receptors in the cortex and striatum, as well as receptor downregulation in the cortex^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Sprague-Dawley (male, 250-270 g)^[1]
Dosage:	30 μg (single treatment); 30 μg (repeated treatment)
Administration:	i.c.v.; single injection (single treatment); i.c.v.; twice daily; 10 days (repeated treatment)
Result:	Abolished U69593-induced antinociception (significant reduction in % MPE vs vehicle) when tested 1, 11, and 30 days post-single 30 μg i.c.v. injection. Did not alter DAMGO- or DPDPE-induced antinociception when tested 1 and 11 days post-single 30 μg i.c.v. injection. Abolished U69593-induced antinociception (significant reduction in % MPE vs vehicle) when tested 1, 2, 5, and 20 days post-last repeated 30 μg i.c.v. twice-daily injection. Abolished DAMGO- and DPDPE-induced antinociception (significant reduction in % MPE vs vehicle) when tested 1 and 2 days post-last repeated 30 μg i.c.v. twice-daily injection. Showed no effect on DAMGO- or DPDPE-induced antinociception at 5 and 20 days post-last repeated 30 μg i.c.v. twice-daily injection. Exhibited magnitude of DAMGO and DPDPE antagonism on day 1 post-last repeated dose equivalent to that of selective μ-antagonist CTOP and δ-antagonist ICI 174,864, respectively.

Animal Model:	Sprague-Dawley (7- to 8-week-old male, 250-300 g, butorphanol dependence model via intracerebroventricular osmotic minipump infusion of butorphanol tartrate at 26 nmol/h for 3 days)^[2]
Dosage:	12 nM/5 μl per rat; 24 nM/5 μl per rat; 48 nM/5 μl per rat; 100 nM/5 μl per rat
Administration:	i.c.v.; 2 doses (3 h before and 48 h after butorphanol infusion start)
Result:	Completely blocked naloxone-precipitated withdrawal signs of escape behavior, teeth-chattering, wet shakes, ptosis, body weight loss (>3%), and reversed hypothermia to increased rectal temperatures. Significantly blocked diarrhea at 12 nM dose. Significantly blocked diarrhea and attenuated forepaw tremors at 24 nM dose. Had no effect on withdrawal signs of yawning, ejaculation, or urination. Prevented butorphanol-induced increases in [³H]U-69,593 K_D values in the cortex (4.33 nM, 96% of saline control) and striatum (5.49 nM, 105% of saline control) at 12 nmol dose. Prevented butorphanol-induced decreases in [³H]U-69,593 B_max values in the cortex (59.46 fM/mg protein, 97% of saline control) at 12 nmol dose. Prevented butorphanol-induced supersensitivity of cortical κ-opioid receptors to nor-binaltorphimine itself, blocking the significant reduction in K_i values seen with butorphanol alone.

Molecular Weight

661.79

Formula

C₄₀H₄₃N₃O₆

CAS No.

105618-26-6

Appearance

Solid

Color

White to off-white

SMILES

O[C@]12[C@]34[C@](OC5=C(O)C=CC(C[C@@]2([H])N(CC4)CC6CC6)=C53)([H])C7=C(C8=C([C@@]9([H])[C@]%10%11[C@@](C8)([C@](CC%12=C%11C(O9)=C(C=C%12)O)([H])N(CC%10)CC%13CC%13)O)N7)C1

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : ≥ 100 mg/mL (151.11 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H2O : 33.08 mg/mL (49.99 mM; Need ultrasonic and warming)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.5111 mL	7.5553 mL	15.1105 mL
5 mM	0.3022 mL	1.5111 mL	3.0221 mL
10 mM	0.1511 mL	0.7555 mL	1.5111 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).

Purity & Documentation

Purity: 98.70%

Select Batch:

Data Sheet (290 KB) SDS (393 KB)

COA (264 KB) HNMR (291 KB) RP-HPLC (260 KB) LCMS (109 KB)

Handling Instructions (2659 KB)

References

[1]. Spanagel R, et al. Evidence that nor-binaltorphimine can function as an antagonist at multiple opioid receptor subtypes. Eur J Pharmacol. 1994;264(2):157-162. [Content Brief]

[2]. Jaw SP, et al. Effects of nor-binaltorphimine on butorphanol dependence. Eur J Pharmacol. 1993;239(1-3):133-140. [Content Brief]

[3]. Portoghese PS, et al. Binaltorphimine and nor-binaltorphimine, potent and selective kappa-opioid receptor antagonists. Life Sci. 1987 Mar 30;40(13):1287-92. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

H2O / DMSO	1 mM	1.5111 mL	7.5553 mL	15.1105 mL	37.7763 mL
	5 mM	0.3022 mL	1.5111 mL	3.0221 mL	7.5553 mL
	10 mM	0.1511 mL	0.7555 mL	1.5111 mL	3.7776 mL
	15 mM	0.1007 mL	0.5037 mL	1.0074 mL	2.5184 mL
	20 mM	0.0756 mL	0.3778 mL	0.7555 mL	1.8888 mL
	25 mM	0.0604 mL	0.3022 mL	0.6044 mL	1.5111 mL
	30 mM	0.0504 mL	0.2518 mL	0.5037 mL	1.2592 mL
	40 mM	0.0378 mL	0.1889 mL	0.3778 mL	0.9444 mL
DMSO	50 mM	0.0302 mL	0.1511 mL	0.3022 mL	0.7555 mL
	60 mM	0.0252 mL	0.1259 mL	0.2518 mL	0.6296 mL
	80 mM	0.0189 mL	0.0944 mL	0.1889 mL	0.4722 mL
	100 mM	0.0151 mL	0.0756 mL	0.1511 mL	0.3778 mL

nor-Binaltorphimine Related Classifications

Neurological Disease

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

nor-Binaltorphimine105618-26-6Norbinaltorphimine NorBNIOpioid Receptorκ-opioid receptorδ-opioid receptorbutorphanol dependencerabbit vas deferensratsmouse vas deferensμ-opioid receptorguinea pig ileal longitudinal muscledynorphin 1-17rat cortical membranesInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

nor-Binaltorphimine (Synonyms: Norbinaltorphimine; NorBNI)

Customer Review

Other Forms of nor-Binaltorphimine:

nor-Binaltorphimine Related Antibodies

7 Publications Citing Use of MCE nor-Binaltorphimine

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Opioid Receptor Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

nor-Binaltorphimine Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

nor-Binaltorphimine Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report